Latest Intelligence on Genomics, Proteomics and Pharmacogenomics in Asia-Pacific

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

The impact of IT on next-generation DNA sequencing

The mystery behind why some have a genetic disposition to a certain disease, or why a medicine works for some and not for others, might be revealed sooner than many had anticipated. In the past couple of months, several significant breakthroughs in DNA sequencing technology have been made, giving hope to the researchers that the coveted $1,000 genome is just around the corner.

Published By Datamonitor
21 Apr 2008
CommentWire
CommentWire

RNAi: is the industry losing faith?

RNAi-based drugs were widely viewed as the next big thing after monoclonal antibodies; however, the initial wave of interest seems to be slowing down, largely due to financial constraints. Novartis and Roche recently ended their respective research in this field, highlighting the pharmaceutical industry's immediate need to boost its top line.

Published By Datamonitor
25 Nov 2010
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002

« | 1 | » »|

No help is available.